Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itepekimab mechanism-of-action study in COPD
NL-OMON52084Phase 2Recruiting
- Sponsor
- Sanofi
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of itepekimab in chronic obstructive pulmonary disease (COPD), chronic bronchitis (CB), sponsored by Sanofi. Started Nov 2022; status: recruiting.
02
Drugs
itepekimab
03
Conditions
chronic obstructive pulmonary disease (COPD)chronic bronchitis (CB)
Beyond the preview
Go deeper on NL-OMON52084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52084.